Clinical Trial Update: Ph II CHOP+Velcade in Mediastinal LBCL [Phase 2]

View source ↗

Summary

A Phase II trial of CHOP plus bortezomib (Velcade) for mediastinal large B-cell lymphoma, a form of non-Hodgkin lymphoma, was terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Mediastinal Large B-cell Lymphoma
• Non-hodgkin Lymphoma

Drugs mentioned

• CYCLOPHOSPHAMIDE (Cyclophosphamide)
• Doxorubicin (doxorubicin)
• PREDNISONE (Prednisone)
• Velcade (bortezomib)
• Vincristine (vincristine)

Snippet

Sponsor: Dana-Farber Cancer Institute | Conditions: Non-Hodgkin's Lymphoma | Phase 2 | Status: TERMINATED